Proactive Research analyst Emma Ulker says MaxCyte’s (LON:MXCT) deal with clinical-stage industry leader Allogene Therapeutics (NASDAQ:ALLO) is a clear endorsement of the features of its Flow Electroporation technology.
Described by Allogene as the ‘industry standard’, MXCT’s Flow Electroporation has been chosen to improve yield and efficiency of its lead clinical programmes.